Oligonucleotide Machine Learning for Predictive Medicine Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional methods for identifying oligonucleotide-based medicines (OBMs) are resource- and time-inefficient, relying on trial-and-error screening, and lack the ability to predict pharmacology and target specific tissues or cells, leading to high development costs and sporadic failures.
Innovation Solution
A machine-learned model is used to design and test OBMs in silico, mapping oligonucleotide sequences to biophysical effects, iteratively refining the model to generate a final set of oligonucleotides that accurately correspond to desired biophysical functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional trial-and-error screening methods are used to identify OBMs, then the process can be performed with existing resources, but the process is resource- and time-inefficient and leads to high development costs
Solution Approach 1:
The patent applies preliminary action by using machine learning models to predict OBM pharmacology and efficacy before actual experimental screening. The model is trained on existing data representing OBM structure, pharmacology, and effectiveness, allowing virtual screening and ranking of candidate OBMs prior to wet-lab testing, thereby reducing the time and resources needed for traditional trial-and-error screening
Solution Approach 2:
The patent replaces the mechanical experimental screening process with a computational machine learning system. Instead of physically testing numerous OBM candidates through traditional laboratory methods, the system uses AI algorithms to simulate and predict OBM performance, substituting physical experimentation with computational analysis to accelerate discovery
2Reliability
If traditional trial-and-error screening methods are used, then no advanced computational tools are required, but the process lacks predictability and leads to sporadic failures
Solution Approach 1:
The patent replaces unpredictable mechanical screening with a computational prediction system. The machine learning model processes input data representing OBM structure and pharmacology through algorithmic analysis, providing reliable predictions of biophysical effects and efficacy before experimentation, thereby eliminating the sporadic failures characteristic of trial-and-error approaches
Solution Approach 2:
The patent introduces a machine learning model as an intermediary between OBM design and experimental validation. This computational mediator predicts pharmacological outcomes and identifies promising candidates before wet-lab testing, filtering out unlikely failures early in the process and reducing the impact of sporadic failures on overall development reliability
3Adaptability or versatility
If OBMs are designed without machine learning guidance, then the design process is simpler, but the ability to target specific tissues or cells is limited
Solution Approach 1:
The patent applies local quality by enabling OBMs to be specifically tailored for different tissues and cell types through machine learning-guided design. The model analyzes and predicts tissue-specific pharmacological responses, allowing customization of OBM sequences and chemistries to optimize binding affinity and efficacy for particular target tissues such as the brain or eye, rather than using universal designs
Solution Approach 2:
The patent utilizes parameter changes by adjusting multiple variables in the OBM design space through machine learning optimization. The model evaluates and predicts the effects of varying sequence composition, chemical modifications, and structural parameters to identify optimal combinations for specific tissue targeting, transforming the design process from simple to highly adaptable through computational guidance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the rapid, cost-efficient design of safe and effective OBMs that can precisely target specific tissues or cells, reducing development time and costs while improving the predictability of pharmacology.
Implementation Method 1
Oligonucleotide-based medicine can be designed and tested in silico using a machine-learned model trained on data representative of OBM structure, pharmacology, and effectiveness
Implementation Method 2
OBMs are designed to engage with native DNA or RNA sequences in the cell by Watson Crick hybridization
Data Source
AI summary
A machine-learned model can be trained on and applied to oligonucleotide data. The machine-learned model can be, for example, a neural network, a random forest classifier, or a regression model, and can be trained in one or more stages. The machine-learned model can be applied in design settings, for instance by being configured to predict biophysical effects corresponding to oligonucleotides, by processing real-world experimental or laboratory data, and by retraining the machine-learned model in response to the processed data.